Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.16.
Puma Biotechnology Inc. (PBYI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 3,167,463 | $16,787,554 | +1% | 0% |
| 2. | Eversept Partners Kamran Moghtaderi | 1,426,497 | $7,560,434 | -16% | 0.5% |
| 3. | Great Point Partners Jeffrey Jay And David Kroin | 1,343,628 | $7,121,228 | +23% | 1.1% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 255,300 | $1,353,090 | -11% | 0% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 238,491 | $1,264,003 | -32% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.49 | 28 | Officer | 30 | 2014-04-11 | Filing | |
| $87.35 | 2 | Officer | 2 | 2014-04-09 | Filing | |
| $38.92 | 22,549 | Large Shareholder | 5,686,668 | 2013-11-08 | Filing | |
| $39.60 | 280,700 | Large Shareholder | 5,664,119 | 2013-11-05 | Filing | |
| $40.08 | 54,200 | Large Shareholder | 5,383,419 | 2013-10-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.27 | 5,295 | Officer | 166,678 | 2024-07-02 | Filing | |
| $3.27 | 6,051 | Officer | 120,986 | 2024-07-02 | Filing | |
| $3.27 | 4,349 | Officer | 136,864 | 2024-07-02 | Filing | |
| $3.27 | 18,885 | Large Shareholder, Officer, Director | 7,085,435 | 2024-07-02 | Filing | |
| $3.33 | 27,000 | Director | 350 | 2024-06-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,802,081 | $16,463,011 | 0% | |
| 2. | 1,792,114 | $7,759,854 | 11.27% | |
| 3. | 1,544,532 | $6,687,824 | 0% | |
| 4. | 538,559 | $2,331,960 | 0.23% | |
| 5. | 497,722 | $2,155,270 | 0% |
News See All
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript
Puma Biotechnology, Inc. misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.37. Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Camilla, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded.
5 Best Quality Penny Stocks to Buy
Chimerix, Inc. (NASDAQ:CMRX) is working on treatments for fatal diseases. Chimerix, Inc.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Victoria, and I will be your conference call operator today. At this time, all participants are in a listen-only mode.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Rob, and I will be your conference call operator today. As a reminder, this call is being recorded.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. My name is Diego, and I will be your conference call operator today. As a reminder, this call is being recorded.
5 Most Promising Cancer Stocks According to Analysts
BeiGene, Ltd. (NASDAQ:BGNE) is a Massachusetts-based biotechnology company that focuses on discovering, developing, and commercializing medicines worldwide.
15 Best Affordable Stocks Under $30
The equity markets around the world have continued to decline in 2022 for various reasons.
Puma Biotechnology Inc (PBYI): Are Hedge Funds Right About This Stock?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in...
Billionaire Hedge Funds
